The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review

SCIg represents an important treatment option both for alleviating burden to the Canadian healthcare system and for patients. Substantial cost savings were estimated by switching from IVIg to SCIg. These findings provide evidence to support healthcare decision-making from an economic perspective.